IRBS IR BioSciences Holdings Inc New (CE)

ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced positive results from a study that evaluated its lead anti-Influenza drug, Homspera. The study in animals infected with H5N1 (or "Avian") Influenza virus, which is highly lethal to humans and animals, revealed that Homspera treatment starting 1 day following Influenza infection dramatically reduced symptoms of Influenza infection and increased survival by 60% over infected controls.

Performed at a public University under the guidance of a world-renowned Influenza expert, the study utilized a 'real-world' scenario of highly pathogenic Influenza infection by a clade 2.2 H5N1 virus (A/Whooperswan/Mongolia/244/2005); Homspera treatment commenced 1 day following Influenza infection, which coincided with the first signs of disease symptoms. The study also utilized the most widely accepted model of Influenza infection, the ferret, and 2 different viral infectious doses (an approximate LD50 and 100x LD50 dose) to evaluate differences relative to in initial infection burden. Homspera treatment was found to increase survival by 60% and reduce fever in both viral infectious dose groups. Additionally, Homspera treatment reduced the decrease in body weight seen in the lower viral infectious dose group to levels of uninfected animals.

"We are excited by these findings," asserted ImmuneRegen CEO Michael Wilhelm. "We had preliminary evidence in ferrets suggesting a survival benefit against pandemic avian flu on co-administration, but these studies, showing Homspera's ability to treat highly pathogenic Influenza infection when administered at the onset of symptoms -- reducing the symptoms of the disease and increasing survival -- are validation that Homspera development should be pursued as a stand-alone therapeutic. These studies support our previous seasonal Influenza therapeutic studies, in which we saw similar reductions of symptoms, as well as decreased viral titers, coinciding with Homspera treatment. We believe we've gathered enough convincing animal data to move this program to the clinic."

About ImmuneRegen BioSciences, Inc.

ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.

Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-KSB for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.

Contact: Michael K. Wilhelm ImmuneRegen BioSciences Inc. Phone: 480-922-3926 Email: Email Contact John Fermanis ImmuneRegen BioSciences Inc. Phone: 480-922-3926 Email: Email Contact